The buprenorphine market is estimated to be valued at US$ 3,681.9 million in 2022 and is expected to exhibit a CAGR of 14.5% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Buprenorphine is a semi-synthetic opioid medication that acts as a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. It is predominantly used as a treatment for opioid addiction and chronic pain management. As a partial opioid agonist, buprenorphine reduces the euphoric and sedative effects of full opioid agonists while still providing analgesic effects, making it appealing for pain management. Its ceiling effect also reduces the risk of overdose even if higher doses are administered. Additionally, unlike methadone, buprenorphine can be prescribed through physicians’ offices rather than an opioid treatment program.
Growing prevalence of chronic pain conditions such as lower back pain, arthritis, and neurological pain is expected to drive the growth of buprenorphine market over the forecast period. According to Global Burden of Disease Study, in 2017, low back pain was the single leading cause of disability worldwide. Another key driver for the market growth is growing acceptance of buprenorphine as an effective treatment option for chronic pain management. Buprenorphine offers several advantages over other opioid medications such as high safety profile, minimal risk of overdose, and ease of prescription. Furthermore, increasing commercialization of generic versions of buprenorphine drugs following patent expiration is also anticipated to boost its market value. For instance, Siegfried, Sanofi,
The global buprenorphine market is segmented based on product, application, and region. By product, the sublingual tablets segment held the largest market share in 2020 due to increasing adoption of sublingual tablets for treatment of opioid dependence. Sublingual formulations provide rapid absorption and high relative oral bioavailability as compared to other oral formulations.
Political: Governments across the globe are supporting initiatives to curb drug abuse by promoting generics and affordable treatment options. However, strict regulations could hamper market growth to some extent.
Economic: The growing economic burden of drug abuse disorders worldwide is driving government and private investments in newer treatment avenues. The recovering global economy also favors market expansion.
Social: Increasing public awareness about opioid dependence and availability of effective medications is boosting the adoption of buprenorphine therapy. Stigma reduction programs also encourage more patients to seek proper treatment.
Technological: Continuous R&D is helping introduce newer drug delivery systems like transdermal patches for enhanced efficacy and patient adherence over long term use.
The Global Buprenorphine Market Size is expected to witness high growth, exhibiting CAGR of 14.5% over the forecast period, due to increasing prevalence of opioid dependence worldwide. The United States represents the fastest growing regional market due to robust reimbursement structures and awareness programs promoting buprenorphine therapy.
The North American region dominates the global market and is expected to retain its position over the forecast period. This is attributed to rising consumption of opioids coupled with easy availability of generic drugs and favorable reimbursement policies in countries like the US.
Key players operating in the buprenorphine market are Siegfried, Sanofi, Johnson Matthey, Mallinckrodt, Noramco, Unichem Laboratories, Arevipharma GmbH, Resonance-labs, Sun Pharmaceutical Industries Ltd., Rusan Pharma, Micro Orgo Chem, and Faran Shimi Pharmaceutical Co. Siegfried dominated the market due to its wide product portfolio and commercial presence across regions.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it